Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin

3 Case reports

F. Yamamuro, A. Miki, G. Kondo, T. Maeda, H. Satoh, Satoko Hori, Y. Sawada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: We report three cases of elevated prothrombin time-international normalized ratios (PT-INR) following the initiation of coadministration of warfarin and S-1, a preparation containing tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo). Case summaries: The three cases included 2 men and 1 woman aged 79, 71, and 54 y, respectively. PT-INRs were in the range of 2.0-3.0 before therapy but were elevated to values in the range of 3.79-4.92 within 8-17 days after initiating the coadministration of warfarin (1.5-3.5 mg/d) and S-1 (80-120 mg/d). When the drug interactions in Cases 1-3 were evaluated using the Drug Interaction Probability Scale, each of these cases was assessed as "probable". Discussion: The drug interaction between warfarin and S-1 presumably leads to elevated PT-INR because the 5-fluorouracil (5-FU), which is metabolite of FT in S-1, inhibits the metabolic processing of S-warfarin by cytochrome P450 (CYP) 2C9. However, individual differences in the metabolic production of 5-FU from FT because of genetic polymorphisms in CYP2A6 and individual variation in the levels of renal function may lead to complications when 5-FU is coadministered with warfarin as compared to when 5-FU is administered alone. Conclusion: It is essential that the dosage level of warfarin is appropriately adjusted by frequent PT-INR measurements when warfarin and S-1 are coadministered.

Original languageEnglish
Pages (from-to)700-704
Number of pages5
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume49
Issue number11
DOIs
Publication statusPublished - 2011 Nov 1
Externally publishedYes

Fingerprint

International Normalized Ratio
Prothrombin Time
Warfarin
Individuality
Antineoplastic Agents
Fluorouracil
Drug Interactions
Oxonic Acid
Tegafur
Genetic Polymorphisms
Cytochrome P-450 Enzyme System
Potassium
Kidney

Keywords

  • Drug interaction
  • PT-INR
  • S-1
  • Warfarin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin : 3 Case reports. / Yamamuro, F.; Miki, A.; Kondo, G.; Maeda, T.; Satoh, H.; Hori, Satoko; Sawada, Y.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 49, No. 11, 01.11.2011, p. 700-704.

Research output: Contribution to journalArticle

@article{322e29701d0040b48e68b09540c3b956,
title = "Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin: 3 Case reports",
abstract = "Objective: We report three cases of elevated prothrombin time-international normalized ratios (PT-INR) following the initiation of coadministration of warfarin and S-1, a preparation containing tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo). Case summaries: The three cases included 2 men and 1 woman aged 79, 71, and 54 y, respectively. PT-INRs were in the range of 2.0-3.0 before therapy but were elevated to values in the range of 3.79-4.92 within 8-17 days after initiating the coadministration of warfarin (1.5-3.5 mg/d) and S-1 (80-120 mg/d). When the drug interactions in Cases 1-3 were evaluated using the Drug Interaction Probability Scale, each of these cases was assessed as {"}probable{"}. Discussion: The drug interaction between warfarin and S-1 presumably leads to elevated PT-INR because the 5-fluorouracil (5-FU), which is metabolite of FT in S-1, inhibits the metabolic processing of S-warfarin by cytochrome P450 (CYP) 2C9. However, individual differences in the metabolic production of 5-FU from FT because of genetic polymorphisms in CYP2A6 and individual variation in the levels of renal function may lead to complications when 5-FU is coadministered with warfarin as compared to when 5-FU is administered alone. Conclusion: It is essential that the dosage level of warfarin is appropriately adjusted by frequent PT-INR measurements when warfarin and S-1 are coadministered.",
keywords = "Drug interaction, PT-INR, S-1, Warfarin",
author = "F. Yamamuro and A. Miki and G. Kondo and T. Maeda and H. Satoh and Satoko Hori and Y. Sawada",
year = "2011",
month = "11",
day = "1",
doi = "10.5414/CP201494",
language = "English",
volume = "49",
pages = "700--704",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "11",

}

TY - JOUR

T1 - Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin

T2 - 3 Case reports

AU - Yamamuro, F.

AU - Miki, A.

AU - Kondo, G.

AU - Maeda, T.

AU - Satoh, H.

AU - Hori, Satoko

AU - Sawada, Y.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objective: We report three cases of elevated prothrombin time-international normalized ratios (PT-INR) following the initiation of coadministration of warfarin and S-1, a preparation containing tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo). Case summaries: The three cases included 2 men and 1 woman aged 79, 71, and 54 y, respectively. PT-INRs were in the range of 2.0-3.0 before therapy but were elevated to values in the range of 3.79-4.92 within 8-17 days after initiating the coadministration of warfarin (1.5-3.5 mg/d) and S-1 (80-120 mg/d). When the drug interactions in Cases 1-3 were evaluated using the Drug Interaction Probability Scale, each of these cases was assessed as "probable". Discussion: The drug interaction between warfarin and S-1 presumably leads to elevated PT-INR because the 5-fluorouracil (5-FU), which is metabolite of FT in S-1, inhibits the metabolic processing of S-warfarin by cytochrome P450 (CYP) 2C9. However, individual differences in the metabolic production of 5-FU from FT because of genetic polymorphisms in CYP2A6 and individual variation in the levels of renal function may lead to complications when 5-FU is coadministered with warfarin as compared to when 5-FU is administered alone. Conclusion: It is essential that the dosage level of warfarin is appropriately adjusted by frequent PT-INR measurements when warfarin and S-1 are coadministered.

AB - Objective: We report three cases of elevated prothrombin time-international normalized ratios (PT-INR) following the initiation of coadministration of warfarin and S-1, a preparation containing tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo). Case summaries: The three cases included 2 men and 1 woman aged 79, 71, and 54 y, respectively. PT-INRs were in the range of 2.0-3.0 before therapy but were elevated to values in the range of 3.79-4.92 within 8-17 days after initiating the coadministration of warfarin (1.5-3.5 mg/d) and S-1 (80-120 mg/d). When the drug interactions in Cases 1-3 were evaluated using the Drug Interaction Probability Scale, each of these cases was assessed as "probable". Discussion: The drug interaction between warfarin and S-1 presumably leads to elevated PT-INR because the 5-fluorouracil (5-FU), which is metabolite of FT in S-1, inhibits the metabolic processing of S-warfarin by cytochrome P450 (CYP) 2C9. However, individual differences in the metabolic production of 5-FU from FT because of genetic polymorphisms in CYP2A6 and individual variation in the levels of renal function may lead to complications when 5-FU is coadministered with warfarin as compared to when 5-FU is administered alone. Conclusion: It is essential that the dosage level of warfarin is appropriately adjusted by frequent PT-INR measurements when warfarin and S-1 are coadministered.

KW - Drug interaction

KW - PT-INR

KW - S-1

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=80054788133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054788133&partnerID=8YFLogxK

U2 - 10.5414/CP201494

DO - 10.5414/CP201494

M3 - Article

VL - 49

SP - 700

EP - 704

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 11

ER -